{"transactions":[{"id":4627246,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-09-26T00:20:46.000Z","date":"2026-09-23","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026."}],"balance_after":4000,"derivative":{"exercise_price":57.66,"expiration_date":"2034-09-22","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001193125-26-403099","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000119312526403099/ownership.xml","form_type":"4"}},{"id":4627245,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-26T00:20:46.000Z","date":"2026-09-23","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock was acquired pursuant to a grant of restricted stock units (\"RSUs\"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This RSU award vests in full, one year following September 23, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Stock Split\"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split."}],"balance_after":3904,"source":{"system":"sec-edgar","filing":"0001193125-26-403099","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000119312526403099/ownership.xml","form_type":"4"}},{"id":1029892,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-10-01T23:50:18.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025."}],"balance_after":8000,"derivative":{"exercise_price":56.9,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001193125-25-227233","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000119312525227233/ownership.xml","form_type":"4"}},{"id":1300922,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-01-18T01:32:48.000Z","date":"2024-09-18","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 18, 2024."}],"balance_after":120000,"derivative":{"exercise_price":1.26,"expiration_date":"2032-09-17","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-25-006883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000095017025006883/ownership.xml","form_type":"5"}},{"id":1357347,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-20T16:15:03.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":8706,"price":0.5485,"value":4775.241,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":723363,"source":{"system":"sec-edgar","filing":"0000950170-24-129257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024129257/ownership.xml","form_type":"4"}},{"id":1374333,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-06T16:15:14.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":10609,"price":0.8649,"value":9175.7241,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":732069,"source":{"system":"sec-edgar","filing":"0000950170-24-122336","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024122336/ownership.xml","form_type":"4"}},{"id":1382399,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-23T16:15:04.000Z","date":"2024-10-21","kind":"sale","planned":false,"acquired":false,"shares":9752,"price":0.779,"value":7596.808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":742678,"source":{"system":"sec-edgar","filing":"0000950170-24-116645","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024116645/ownership.xml","form_type":"4"}},{"id":1390830,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-04T16:15:04.000Z","date":"2024-10-03","kind":"sale","planned":false,"acquired":false,"shares":1493,"price":0.8148,"value":1216.4964,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":752430,"source":{"system":"sec-edgar","filing":"0000950170-24-112912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024112912/ownership.xml","form_type":"4"}},{"id":1425464,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-22T16:15:03.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":5390,"price":0.7413,"value":3995.607,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7384 to $0.745. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":753923,"source":{"system":"sec-edgar","filing":"0000950170-24-099846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024099846/ownership.xml","form_type":"4"}},{"id":1427791,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-20T16:15:02.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":3091,"price":0.7595,"value":2347.6145,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":759313,"source":{"system":"sec-edgar","filing":"0000950170-24-099102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024099102/ownership.xml","form_type":"4"}},{"id":1438865,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-07T16:15:04.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":10847,"price":0.7348,"value":7970.3756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":762404,"source":{"system":"sec-edgar","filing":"0000950170-24-092807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024092807/ownership.xml","form_type":"4"}},{"id":1449983,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-23T16:28:25.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":9731,"price":0.7501,"value":7299.2231,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":773251,"source":{"system":"sec-edgar","filing":"0000950170-24-085669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024085669/ownership.xml","form_type":"4"}},{"id":1460198,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-03T16:11:17.000Z","date":"2024-07-02","kind":"sale","planned":false,"acquired":false,"shares":1489,"price":0.72,"value":1072.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":782982,"source":{"system":"sec-edgar","filing":"0000950170-24-081511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024081511/ownership.xml","form_type":"4"}},{"id":1503807,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-23T17:24:13.000Z","date":"2024-05-21","kind":"sale","planned":false,"acquired":false,"shares":5149,"price":0.7923,"value":4079.5527,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7899 to $0.7994. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":784471,"source":{"system":"sec-edgar","filing":"0000950170-24-064052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024064052/ownership.xml","form_type":"4"}},{"id":1507284,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-21T16:35:03.000Z","date":"2024-05-17","kind":"sale","planned":false,"acquired":false,"shares":3075,"price":0.7493,"value":2304.0975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":789620,"source":{"system":"sec-edgar","filing":"0000950170-24-062982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024062982/ownership.xml","form_type":"4"}},{"id":1524850,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-07T16:15:37.000Z","date":"2024-05-03","kind":"sale","planned":false,"acquired":false,"shares":10240,"price":0.796,"value":8151.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":792695,"source":{"system":"sec-edgar","filing":"0000950170-24-054512","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024054512/ownership.xml","form_type":"4"}},{"id":1536914,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-23T16:15:12.000Z","date":"2024-04-19","kind":"sale","planned":false,"acquired":false,"shares":9601,"price":0.7506,"value":7206.5106,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7460 to $0.7562. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":802935,"source":{"system":"sec-edgar","filing":"0000950170-24-046908","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024046908/ownership.xml","form_type":"4"}},{"id":1547893,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-04T16:15:16.000Z","date":"2024-04-02","kind":"sale","planned":false,"acquired":false,"shares":1533,"price":0.772,"value":1183.476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7513 to $0.7801. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":812536,"source":{"system":"sec-edgar","filing":"0000950170-24-041810","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024041810/ownership.xml","form_type":"4"}},{"id":1625534,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-22T16:18:22.000Z","date":"2024-02-21","kind":"sale","planned":false,"acquired":false,"shares":5155,"price":0.7081,"value":3650.2555,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7002 to $0.7098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":814069,"source":{"system":"sec-edgar","filing":"0000950170-24-018785","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024018785/ownership.xml","form_type":"4"}},{"id":1625533,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-22T16:18:22.000Z","date":"2024-02-20","kind":"sale","planned":false,"acquired":false,"shares":3097,"price":0.6952,"value":2153.0344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":819224,"source":{"system":"sec-edgar","filing":"0000950170-24-018785","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024018785/ownership.xml","form_type":"4"}},{"id":1656948,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-06T16:38:27.000Z","date":"2024-02-05","kind":"sale","planned":false,"acquired":false,"shares":41421,"price":0.67,"value":27752.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":822321,"source":{"system":"sec-edgar","filing":"0000950170-24-011769","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024011769/ownership.xml","form_type":"4"}},{"id":1671050,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-25T16:15:23.000Z","date":"2024-01-23","kind":"sale","planned":false,"acquired":false,"shares":9500,"price":0.6704,"value":6368.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6683 to $0.6794. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":863742,"source":{"system":"sec-edgar","filing":"0000950170-24-007406","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024007406/ownership.xml","form_type":"4"}},{"id":1684355,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-08T16:15:11.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":1664,"price":0.639,"value":1063.296,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":873242,"source":{"system":"sec-edgar","filing":"0000950170-24-002935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024002935/ownership.xml","form_type":"4"}},{"id":1732881,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-21T17:00:35.000Z","date":"2023-11-20","kind":"sale","planned":true,"acquired":false,"shares":4382,"price":1.6905,"value":7407.771,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.69 to $1.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":874906,"source":{"system":"sec-edgar","filing":"0001209191-23-056313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123056313/doc4.xml","form_type":"4"}},{"id":1732880,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-21T17:00:35.000Z","date":"2023-11-17","kind":"sale","planned":true,"acquired":false,"shares":2689,"price":1.6311,"value":4386.0279,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.61 to $1.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":879288,"source":{"system":"sec-edgar","filing":"0001209191-23-056313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123056313/doc4.xml","form_type":"4"}},{"id":1756259,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-23T17:00:11.000Z","date":"2023-10-19","kind":"sale","planned":true,"acquired":false,"shares":8581,"price":1.58,"value":13557.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":881977,"source":{"system":"sec-edgar","filing":"0001209191-23-053349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123053349/doc4.xml","form_type":"4"}},{"id":1764369,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-05T17:00:15.000Z","date":"2023-10-03","kind":"sale","planned":true,"acquired":false,"shares":1325,"price":1.9763,"value":2618.5975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.95 to $2.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":890558,"source":{"system":"sec-edgar","filing":"0001209191-23-052229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123052229/doc4.xml","form_type":"4"}},{"id":1776477,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-09-21T00:07:26.000Z","date":"2023-09-19","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023."}],"balance_after":85000,"derivative":{"exercise_price":0.68,"expiration_date":"2031-09-18","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-23-050221","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919123050221/doc4.xml","form_type":"4"}},{"id":1800869,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-21T17:00:13.000Z","date":"2023-08-18","kind":"sale","planned":true,"acquired":false,"shares":4055,"price":2.7898,"value":11312.639,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.77 to $2.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":891883,"source":{"system":"sec-edgar","filing":"0001209191-23-046732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123046732/doc4.xml","form_type":"4"}},{"id":1800868,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-21T17:00:13.000Z","date":"2023-08-17","kind":"sale","planned":true,"acquired":false,"shares":11361,"price":2.4955,"value":28351.3755,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.45 to $2.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":895938,"source":{"system":"sec-edgar","filing":"0001209191-23-046732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123046732/doc4.xml","form_type":"4"}},{"id":1824920,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-21T17:00:12.000Z","date":"2023-07-19","kind":"sale","planned":true,"acquired":false,"shares":8342,"price":3.5615,"value":29710.033,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.53 to $3.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":907299,"source":{"system":"sec-edgar","filing":"0001209191-23-043121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123043121/doc4.xml","form_type":"4"}},{"id":1834044,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-06T17:00:14.000Z","date":"2023-07-05","kind":"sale","planned":true,"acquired":false,"shares":5275,"price":3.0451,"value":16062.9025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.96 to $3.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,288 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2023."}],"balance_after":915641,"source":{"system":"sec-edgar","filing":"0001209191-23-041583","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123041583/doc4.xml","form_type":"4"}},{"id":1884827,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-19T17:00:22.000Z","date":"2023-05-18","kind":"sale","planned":true,"acquired":false,"shares":4536,"price":4.214,"value":19114.704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.04 to $4.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":916628,"source":{"system":"sec-edgar","filing":"0001209191-23-031074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123031074/doc4.xml","form_type":"4"}},{"id":1915661,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-21T16:05:10.000Z","date":"2023-04-19","kind":"sale","planned":true,"acquired":false,"shares":8408,"price":3.7087,"value":31182.7496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.  These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.64 to $3.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":921164,"source":{"system":"sec-edgar","filing":"0001209191-23-025114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123025114/doc4.xml","form_type":"4"}},{"id":1996160,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-23T17:00:33.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":5122,"price":6.6254,"value":33935.2988,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.54 to $6.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":929572,"source":{"system":"sec-edgar","filing":"0001209191-23-012250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123012250/doc4.xml","form_type":"4"}},{"id":2033266,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T17:00:20.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":617500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":1836875,"derivative":{"exercise_price":6.65,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":617500},"source":{"system":"sec-edgar","filing":"0001209191-23-006988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123006988/doc4.xml","form_type":"4"}},{"id":2033265,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-03T17:00:20.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":332500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":934964,"source":{"system":"sec-edgar","filing":"0001209191-23-006988","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123006988/doc4.xml","form_type":"4"}},{"id":2048786,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-23T19:00:13.000Z","date":"2023-01-19","kind":"sale","acquired":false,"shares":34435,"price":5.0777,"value":174850.5995,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 3,009 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on December 30, 2022."}],"balance_after":601607,"source":{"system":"sec-edgar","filing":"0001209191-23-004499","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000120919123004499/doc4.xml","form_type":"4"}},{"id":2108763,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-21T17:47:52.000Z","date":"2022-11-18","kind":"sale","acquired":false,"shares":4515,"price":7.2669,"value":32810.0535,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.23 to $7.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":633033,"source":{"system":"sec-edgar","filing":"0000899243-22-036553","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924322036553/doc4.xml","form_type":"4"}},{"id":2154398,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-09-21T00:43:21.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022."}],"balance_after":20400,"derivative":{"exercise_price":3.47,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001209191-22-050809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919122050809/doc4.xml","form_type":"4"}},{"id":2154397,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-21T00:43:21.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":10200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock was acquired pursuant to a grant of restricted stock units (\"RSUs\"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This RSU award vests in full, one year following September 16, 2022."}],"balance_after":28560,"source":{"system":"sec-edgar","filing":"0001209191-22-050809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919122050809/doc4.xml","form_type":"4"}},{"id":2178401,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-19T16:05:21.000Z","date":"2022-08-18","kind":"sale","acquired":false,"shares":4564,"price":7.7626,"value":35428.5064,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.67 to $7.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":637548,"source":{"system":"sec-edgar","filing":"0000899243-22-029271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924322029271/doc4.xml","form_type":"4"}},{"id":2181983,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-08-17T17:59:33.000Z","date":"2022-08-16","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":642112,"source":{"system":"sec-edgar","filing":"0000899243-22-029046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924322029046/doc4.xml","form_type":"4"}},{"id":2212169,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-06T07:30:10.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":89375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":89375,"derivative":{"exercise_price":4.13,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":89375},"source":{"system":"sec-edgar","filing":"0000899243-22-025231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924322025231/doc4.xml","form_type":"4"}},{"id":2212168,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-07-06T07:30:10.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":48125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,822 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022."}],"balance_after":542112,"source":{"system":"sec-edgar","filing":"0000899243-22-025231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924322025231/doc4.xml","form_type":"4"}},{"id":2260281,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-23T16:44:47.000Z","date":"2022-05-18","kind":"sale","acquired":false,"shares":29135,"price":4.3335,"value":126256.5225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.19 to $4.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":492165,"source":{"system":"sec-edgar","filing":"0000899243-22-019216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924322019216/doc4.xml","form_type":"4"}},{"id":2308661,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-04T16:23:03.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":585000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":585000,"derivative":{"exercise_price":9.15,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":585000},"source":{"system":"sec-edgar","filing":"0000899243-22-013332","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924322013332/doc4.xml","form_type":"4"}},{"id":2308660,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-04T16:23:03.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":521300,"source":{"system":"sec-edgar","filing":"0000899243-22-013332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924322013332/doc4.xml","form_type":"4"}},{"id":2513722,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-11-15T22:08:42.000Z","date":"2021-11-11","kind":"grant","acquired":true,"shares":36720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option vests in equal monthly installments over the three-year period beginning on November 11, 2021."}],"balance_after":36720,"derivative":{"exercise_price":13.55,"expiration_date":"2029-11-10","underlying":"Common Stock","underlying_shares":36720},"source":{"system":"sec-edgar","filing":"0001209191-21-064508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919121064508/doc4.xml","form_type":"4"}},{"id":2513721,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-15T22:08:42.000Z","date":"2021-11-11","kind":"grant","acquired":true,"shares":18360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock was acquired pursuant to a grant of restricted stock units (\"RSUs\").  Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This RSU award vests over three years in equal annual installments beginning on November 11, 2021."}],"balance_after":18360,"source":{"system":"sec-edgar","filing":"0001209191-21-064508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919121064508/doc4.xml","form_type":"4"}},{"id":2708415,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-18T17:08:55.000Z","date":"2021-05-17","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on May 17, 2022, with the remainder vesting in twelve quarterly installments thereafter."}],"balance_after":500000,"derivative":{"exercise_price":23.74,"expiration_date":"2031-05-17","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-21-019779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924321019779/doc4.xml","form_type":"4"}},{"id":2708414,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-18T17:08:55.000Z","date":"2021-05-17","kind":"grant","acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares reported in this transaction represent RSUs issued under the Plan. 25% of these RSUs shall vest on May 17, 2022, with the remainder vesting in twelve quarterly installmenters thereafter."}],"balance_after":206300,"source":{"system":"sec-edgar","filing":"0000899243-21-019779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924321019779/doc4.xml","form_type":"4"}},{"id":2708413,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-18T17:08:55.000Z","date":"2021-05-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 17, 2022."}],"balance_after":36300,"source":{"system":"sec-edgar","filing":"0000899243-21-019779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924321019779/doc4.xml","form_type":"4"}},{"id":3067801,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-05T21:42:27.000Z","date":"2020-08-03","kind":"purchase","acquired":true,"shares":6300,"price":17,"value":107100.0,"ownership":{"direct":true},"balance_after":6300,"source":{"system":"sec-edgar","filing":"0000899243-20-021577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924320021577/doc4.xml","form_type":"4"}},{"id":3072638,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T18:39:11.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in equal quarterly installments over three years, with the first installment vesting on October 29, 2020."}],"balance_after":45000,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-20-020920","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000089924320020920/doc4.xml","form_type":"4"}}]}